51. Patent blue: a novel vital dye in vitreoretinal surgery
- Author
-
Stefan Mennel, Jörg C. Schmidt, Andreas Tietjen, Carsten H. Meyer, and Eduardo B. Rodrigues
- Subjects
Pars plana ,Proliferative vitreoretinopathy ,medicine.medical_specialty ,Visual acuity ,genetic structures ,medicine.medical_treatment ,Vitrectomy ,Absorption ,chemistry.chemical_compound ,Ophthalmology ,medicine ,Rosaniline Dyes ,Humans ,Prospective Studies ,Coloring Agents ,Macular hole ,business.industry ,Spectrum Analysis ,Vitreoretinopathy, Proliferative ,Retinal ,Epiretinal Membrane ,General Medicine ,medicine.disease ,Retinal Perforations ,eye diseases ,Sensory Systems ,Staining ,Surgery ,medicine.anatomical_structure ,chemistry ,sense organs ,Epiretinal membrane ,medicine.symptom ,business ,Follow-Up Studies - Abstract
Purpose: To determine a novel vital dye (patent blue; Blueron®) for vitreoretinal surgery in a prospective consecutive case series. Methods: Five patients with either idiopathic epiretinal membrane (ERM; n = 2), proliferative vitreoretinopathy (n = 2), or a macular hole (n = 1) underwent a three-port pars plana vitrectomy. Patent blue assisted staining of the retinal surface followed by a consecutive peeling of the ERM (n = 4) or of the internal limiting membrane (ILM; n = 1) was performed. The main outcome measures were quality of intraoperative visualization of preretinal structures and postoperative visual acuity. Results: The dye induced a moderate staining (++) of the ERM and a mild staining (+) of the ILM. Complete ERM and ILM removal was successfully achieved in all cases. A mean visual improvement of three Snellen lines was observed 6 months postoperatively. No visual field defects or visible retinal pigment epithelial changes were present 6 months postoperatively. Conclusion: Patent blue, a novel dye for intraocular applications, may be added as an alternative dye in chromovitrectomy.
- Published
- 2005